We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Ultrasound Activates Nanoparticle Drug Delivery

By Biotechdaily staff writers
Posted on 26 Jan 2006
Targeted nanoparticles, which bind to molecules found only on the surfaces of tumor cells, have shown remarkable potential for increasing the effectiveness of anticancer agents while decreasing their possible side effects. More...
Now, investigators at Washington University School of Medicine (St. Louis, MO, USA) have taken targeting one step further by using ultrasound to increase the efficiency with which the targeted nanoparticles deliver drugs into cells.

Publishing their study in the December 2005 issue of the journal Ultrasound in Medicine & Biology, a group led by Samuel Wickline, M.D., director of the Siteman Center of Cancer Nanotechnology Excellence at Washington University, and Gregory Lanza, M.D., performed studies utilizing the liquid perfluorocarbon nanoparticles, which they have been developing as targeted cancer drug delivery agents over the past several years. At least one such compound is being planned to start human clinical trials within the next year or so. The researchers also used commercially available diagnostic ultrasound equipment, the same equipment that obstetricians currently use to generate sonograms of a developing fetus, to generate focused ultrasonic energy designed to enhance drug delivery.

In this study, the nanoparticles were constructed to display a molecule that binds specifically to a protein known as alpha-beta-v3, which is found on the surface of specific types of cancer cells, including melanoma cells. The investigators loaded the nanoparticles with a fluorescent dye, instead of an anticancer drug, to follow the outcome of the nanoparticles and their cargo when combined with melanoma cells growing in culture.

After mixing the nanoparticles with cultured melanoma cells, the investigators applied ultrasonic energy for five minutes. Using a fluorescence microscope, the researchers noted that the cells subjected to ultrasound took up about 10 times more of the fluorescent dye than when no ultrasound is applied. The investigators captured images of the dye streaming into the cell's plasma membrane and then into the cytoplasm. Control tests using ultrasound energy and no nanoparticles demonstrated that cells were not damaged by the application of ultrasonic energy for five minutes.

The researchers observed that these findings supported the theory that ultrasound augments the exchange of molecules between the fat-soluble nanoparticle components and the lipids that comprise the cell membrane. They also commented in their study that enhanced, nanoparticle-aided drug delivery using widely available ultrasound equipment could greatly improve the safety of cancer therapy while reducing the amount of drug used and lowering the cost of therapy.




Related Links:
Washington University School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.